This disclosure relates to ester compounds formed from gamma-branched aliphatic alcohols, lubricating oil base stocks comprising such ester compounds, lubricating oil compositions comprising such ester compounds, and method of making such base stocks. The lubricating oil base stocks comprising the ester compounds exhibit desirable lubricating properties such as polarity.

Described herein are methods of oxidative coupling of aryl boron reagents with sp.sup.3-carbon nucleophiles, and ambient decarboxylative arylation of malonate half-esters via oxidative catalysis.

Described herein are methods of oxidative coupling of aryl boron reagents with sp.sup.3-carbon nucleophiles, and ambient decarboxylative arylation of malonate half-esters via oxidative catalysis.

The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPAR modulation such as diabetes.

This disclosure relates to ester compounds derived from neo-alcohol, lubricating oil base stocks comprising such ester compounds, lubricating oil compositions comprising such ester compounds, and method for making such compounds and/or base stocks. The lubricating oil base stocks comprising the ester compounds exhibit desirable lubricating properties such as polarity and oxidation stability.

This disclosure relates to ester compounds formed from gamma-branched aliphatic alcohols, lubricating oil base stocks comprising such ester compounds, lubricating oil compositions comprising such ester compounds, and method of making such base stocks. The lubricating oil base stocks comprising the ester compounds exhibit desirable lubricating properties such as polarity.

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects.

The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPAR modulation such as diabetes.